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Abstract Cerebral presenilin-1 protein (PS-1) is normally 
composed of the amino-terminal fragment (NTF) with Mr 28 
kDa and the carboxy-terminal fragment (CTF) with 18 kDa. We 
analyzed human PS-1 in brains with early-onset familial 
Alzheimer's disease (FAD) with and without PS-1 mutations to 
study whether mutated PS-1 was abnormally metabolized. 
Cerebral PS-1 were found to be cleaved into two fragments of 
NTF and CTF independently of the occurrence of PS-1 mutation 
in human brains. A small portion of PS-1 was recently found to 
suffer another processing by caspase-3, an apoptosis-related 
cysteine protease. In contrast to the recent finding that the 
Volga-German mutation on presenilin-2 (PS-2) affects the 
increasing caspase-3 PS-2 fragment, the PS-1 mutation did not 
cause a significant change in PS-1 fragmentation. We conclude 
that PS-1 fragmentation and other (probably caspase-3-
mediated) digestion following apoptosis occur independently of 
PS-1 mutations. 
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1. Introduction 
Alzheimer's disease (AD) is a progressive intellectual failure 
in elderly people. The causal genes have been identified as 
presenilin 1 (PS-1) on chromosome 14q24.3 [1,2], presenilin 2 
(PS-2) on chromosome lq42.1 [3,4] and APP on chromosome 
21 [5,6] while the apolipoprotein E allele e4 has been estab-
lished to be a risk factor located on chromosome 19 [7]. Pre-
senilin genes are members of a novel highly conserved family 
[8] whose function is not fully understood, and are expressed 
widely not only in the brain but also in other tissues. In all 
tissues, PS-1 is found to be essentially cleaved into two frag-
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ments : the amino-terminal fragment (NTF) with Mr 28 k D a 
and the carboxy-terminal fragment (CTF) with M r 18 k D a [9-
12]. This fragmentation was claimed to be affected by the PS-1 
mutat ion [13,14]. However, there are reports describing the 
different effects of the PS-1 mutat ion on PS-1 cleavage in 
cultured cells, animals and human brain [9,15,16]. More evi-
dence should accumulate for PS-1 in human tissues to obtain 
concrete conclusions. Here, we studied human brains with and 
without PS-1 mutat ions to address this question and provide 
more detailed information on PS-1 processing in brain. 
2. Materials and methods 
2.1. Preparation of monoclonal and polyclonal antibodies 
Polyclonal and monoclonal antibodies were against NTF and CTF 
of PS-1, respectively. To prepare NTF antibodies, mice and rabbits 
were immunized with the synthetic peptide (DNRER-
QEHNDRRSLGHPEPLSNGRPQ) to produce a polyclonal antibody 
(AD3N) and a monoclonal antibody (PSN2) [17]. To prepare CTF 
antibodies, mice and rabbits were immunized with the synthetic pep-
tide (MAEGDPEAQRRVSKNSKYNAESTERESQDTV) to produce 
polyclonal antibodies (AD3L and mAD3L), respectively [17]. 
2.2. Preparation of PS-1 from human brains 
The brain tissues of subjects with early-onset FAD analyzed here 
carried the PS-1 mutations of Ile143Thr, Met146Leu, His163Arg, 
Ala246Glu and Cys410Tyr [1,4,18]. Brain tissues were homogenized 
with 50 mM Tris-Cl buffer (pH7.6), 150 mM NaCl containing 0.1 
mM diisopropyl fluoro-phosphate, 0.5 mM phenylmethylsulfonyl flu-
oride, 1 ug/ml l-chloro-3-tosylamino-7-amino-2-heptanone, 1 ug/ml 
antipain, 0.1 ug/ml pepstatin, 1 ug/ml leupeptin (TS buffer) followed 
by ultracentrifugation at 100000Xg for 20 min at 4°C. The super-
natant was saved as the soluble fraction. The resultant pellet was 
sequentially extracted with 1% Triton X-100 in TS buffer (Tx buffer), 
1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS in TS buffer 
(RIPA buffer) and 2%o SDS in TS buffer. The membrane fraction 
extracted with Tx buffer was further applied onto affinity column 
coupled to PSN2 or AD3L, specifically eluted with 0.1 M glycine-
HC1 (pH 2.5) and immediately neutralized. These monoclonal and 
polyclonal antibodies (PSN2, AD3N and AD3L) were purified by 
affinity chromatography coupled with the relevant antigen synthetic 
peptides. 
2.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PA GE) and immunoblotting 
SDS-PAGE was carried under reducing conditions, and proteins in 
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gels were transferred on PVDF membrane (MSI). The membrane was 
blocked with 3% gelatin, incubated with PSN2 followed by the horse-
radish peroxidase (HRP)-conjugated second antibody. The color was 
developed with 4-chloro-l-naphthol. 
2.4. Quantitation of protein concentration 
Protein concentration was determined by measuring the absorption 
at 562 nm using the BCA protein assay kit (Pierce, IL). 
3. Results and discussion 
3.1. Gel electrophoretic analysis of human brain PS-1 
To get a specific and high recovery of PS-1 from human 
brains, we used the two-step detection method to identify PS-
1. We used the two antibodies for immunoprecipitation as the 
first step and Western blotting as the second step. AD3N and 
PSN2 were used to detect NTF while AD3L and mAD3L 
were used to detect CTF. As seen in Fig. la, NTF in aged 
normal brains was found predominantly in the membrane 
fraction that was obtained with Tx buffer. CTF was found 
both in the membrane and partly in the cytoskeleton frac-
tions. This result suggests two possibilities. CTF was some-
what insoluble as compared with NTF. Alternatively, a por-
tion of CTF was associated with filamentous cytoskeletons 
such as neurofilaments. Similar results were obtained in PS-
1 derived from brains with sporadic AD (Fig. lb) and early-
onset familial AD with PS-1 mutation (His163Arg) (Fig. lc). 
These data could provide one clear conclusion that the PS-1 
mutation (His163Arg) did not affect PS-1 processing to sup-
port another FAD case with the PS-1 mutation (Gly384Ala) 
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Fig. 1. PS-1 NH2 fragment (NTF) and COOH fragment (CTF) in 
subcellular fraction of human brains. Brain cortices were homogen-
ized and separated into four fractions (see Section 2). Each fraction 
was immunoprecipitated with affinity-purified AD3N or AD3L fol-
lowed by gel electrophoresis/Western blotting with PSN2 or 
mAD3L, respectively, a: aged normal, b: sporadic AD and c: fa-
milial AD with PS-1 mutation (His163Arg). Lane 1: supernatant 
fraction extracted with TS buffer; lane 2: supernatant fraction ex-
tracted with 1% Triton X-100; lane 3: supernatant fraction ex-
tracted with RIPA buffer; lane 4: RIPA buffer precipitate fraction. 
Fig. 2. Immunoaffinity column chromatography of PS-1 fragments 
(NTF) in normal, sporadic and familial AD brains. Triton X-100 
supernatant fractions from brains of (a) aged normal subject (0.4 g), 
sporadic AD (0.5 g) and familial AD with PS-1 mutation 
(His163Arg) (0.25 g) were applied onto an affinity-purified AD3N-
coupled affinity column. The PS-1-containing fraction was eluted 
with 0.1 M glycine-HCl, pH 2.5 and immunoblotted with PSN2. 
[16] unlike in previous studies performed in cultured cells 
[13,14]. 
We next attempted to quantitatively obtain PS-1 fragments. 
For this purpose, we prepared an immunoaffinity column to 
obtain the PS-1 fragment. Synthetic peptides used as antigens 
(see Section 2) were coupled with Sepharose 4B. Antibodies 
were applied onto this affinity column followed by washing 
with PBS and eluted with 0.1 M glycine-HCl, pH 2.5. The 
eluent was immediately neutralized with 2 M Trizma. Purified 
antibodies were then coupled to Sepharose 4B. The membrane 
fraction from human brains was applied onto a purified anti-
body-coupled affinity column and eluted (Fig. 2). As seen in 
protein concentrations in Fig. 2, the amounts of PS-1 frag-
ment were different. However, the molecular compositions of 
PS-1 were essentially identical as seen in the result obtained 
from the immunoprecipitation experiment (Fig. 1). 
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Fig. 3. PS-1 fragments (NTF and CTF) in normal, sporadic and familial AD brains. PS-1 fragments (NTF and CTF) were extracted and parti-
ally purified in a semi-quantitative manner and examined by Western blotting as described in Section 2 or in the legend to Fig. 2. Seven inde-
pendent FAD cases with five different PS-1 mutations were examined. The PS-1 mutations examined are Ile143Thr, Met146Leu, His163Arg, 
Ala246Glu and Cys410Tyr. Note the presence of the largest band (caspase-3 fragment) of PS-1 with MT 34 kDa (arrowhead). 
3.2. Effect of PS-1 mutations on PS-1 fragmentation in brains 
with early-onset familial AD bearing PS-1 mutations 
We provisionally concluded that PS-1 processing occurred 
independent on the mutation using the single case (His163Arg). 
This result confirmed a previous finding for a Belgian PS-1 
mutation [16]. To see whether this conclusion is universal, we 
examined PS-1 in familial AD brains (seven independent 
cases) with different mutation sites and different pedigree 
cases with the same mutation site. We prepared NTF and 
CTF that were derived from subjects with normal aged, 
sporadic AD and seven independent familial AD according 
to the method in Fig. 2. As shown in Fig. 3, we observed 
that human PS-1 was cleaved into two fragments (NTF and 
CTF) independent of the PS-1 mutation. It is noteworthy that 
this observation was highly constant and was not influenced 
by the mutation site from exon 5 to exon 12 of PS-1 [2] and 
the two fragments (NTF and CTF) were similarly found in 
both sporadic and familial AD. The amount of PS-1 was 
higher in FAD brains (36 fmol/mg of protein; n-1) than 
sporadic AD brains (16 fmol/mg of protein; n = 44) based 
on quantitative densitometric analysis of Western blotting. 
Although the number of FAD cases is small, this result may 
be interesting if we consider the possibility that the PS-1 mu-
tation affects gene expression of PS-1. 
3.3. Effect of PS-1 mutations on the PS-1 fragment of 
Mr 34 kDa in brains with early-onset familial 
AD bearing PS-1 mutations 
As seen in Fig. 3, we observed NTF with higher molecular 
weight beside NTF with Mx 28 kDa. The largest size of PS-1 
NTF species was estimated to be 34 kDa. This band could be 
the caspase-3 fragment that was recently reported [19-21]. 
This fragment was found to be evidently removed by 
zVAD, a broad-spectrum inhibitor for most mammalian in-
terleukin-l|3-converting enzyme ICE/Ced-3 proteases (cas-
pases), and zDEVD-fmk, a more selective inhibitor of cas-
pase-3 (CPP32) family proteases (caspase-3, -6 and -7) 
[22,23]. More recently, its CTF was isolated and sequenced, 
showing the presence of the consensus site for caspase-3 cleav-
age [24]. It is likely from the point of view of molecular weight 
that the present PS-1 fragment with Afr 34 kDa is a caspase-3 
fragment although we have no evidence to support it. As the 
caspase-3 fragment of PS-2 was reported to be linked with the 
Volga-German mutation (Asn141Ile) of PS-2 located on chro-
mosome lq42.1 [3,4,17], we next examined the effect of PS-1 
mutations on this PS-1 fragment. As Ap production was in-
fluenced by the PS-1 mutation sites [25-28], it is interesting to 
examine whether the 34 kDa NTF (caspase-3 fragment) is 
altered in a mutation site-dependent manner. We studied 
PS-1 in brains from different pedigrees with FAD bearing 
different PS-1 mutations. 
Fig. 4 shows the ratio of 34 kDa NTF/28 kDa NTF. The 
effect seemed to be very dependent on the mutation site. Tak-
Fig. 4. Effect of mutation site on PS-1 on the ratio of 34 kDa NFT 
(caspase-3 fragment)/28 kDa NTF. The immunoreactive PS-1 NTF 
bands with Mr 34 kDa and 28 kDa were quantitated with a densi-
tometer (Shimadzu CS-9000, Kyoto). Sporadic AD cases (« = 44) 
and FAD cases (n = 7) were analyzed and the ratio of 34 kDa NTF/ 
28 kDa NTF is shown as the average ±S.E. of three independent 
analyses. 
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ing into consideration experimental deviation, the present 
data may suggest that the 34 k D a N T F (caspase-3 fragment) 
of PS-1 was not tightly associated with PS-1 mutat ions. We 
could not find a significant difference in the ratio of this 34 
k D a NTF/28 k D a N T F between sporadic A D and familial 
A D bearing PS-1 mutat ions (data not shown). In spite of 
the present results on PS-1, an involvement of caspase-3 in 
A D pathogenesis may be important to understand the pa tho-
genesis of F A D with PS-2 mutations. Caspase-3 is widely 
believed to play a role in mammalian apoptosis (programmed 
cell death), an evolutionarily conserved form of cellular sui-
cide. If this enzyme is related to A D pathogenesis, it is very 
interesting because it gives hope for drug treatment for A D 
patients. A recent report is suggestive of the involvement of 
caspase-3 in the pathological metabolism of PS-2 [19] but this 
still needs to be studied more. It is wor th noting that the 
expression amounts of presenilin (PS-1 and PS-2) themselves 
could be a potent factor to influence the processing of pres-
enilin as previously described [9]. Therefore, the site-specific 
effects of the mutat ions seen in Fig. 4 might come from the 
different amounts of mutated PS-1 expressed in human 
brains. These results on the PS-1 mutat ions are different 
from previous ones in cultured cells or transgenic mice 
[9,13,14]. We believe that both their data [9,13,14] and our 
data [15,16] are true since the apparent discrepancy comes 
from the physiological expression or experimental expression. 
Thus, the level of PS-1 gene expression is a critical issue if we 
consider the possibility that the full-sized PS-1 plays a differ-
ent role from PS-1 fragments or the gene product is in com-
petitive balance with other molecules. It is suggested that the 
PS-1 mutat ion be considered at least in the relation among 
PS-1, PS-2, and [3APP but it has no influence on the conven-
tional and 34 k D a NTF-generat ing (caspase-3) cleavage of 
mutated PS-1 at least in human brains. 
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